ASCO 2024

First-in-Human Trial of M9140, an Anti-CEACAM5 Antibody–Drug Conjugate (ADC) with Exatecan Payload, in Patients (pts) with Metastatic Colorectal Cancer (mCRC)

Kopetz | Oral #3000

Avelumab + Axitinib vs Sunitinib in Patients with Advanced Renal Cell Carcinoma: Final Overall Survival Analysis from the JAVELIN Renal 101 Phase 3 Trial

Motzer | Oral #4508

A Phase I Study of Highly Potent Oral ATR Inhibitor (ATRi) Tuvusertib plus Oral PARP Inhibitor (PARPi) Niraparib in Patients with Solid Tumors

Yap | Oral #3018

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes from JAVELIN Bladder 100 in Patients with Low Tumor Burden

Bellmunt | Poster #4566

Pharmacodynamic (PD) and Immunophenotyping Analyses of ATR Inhibitor (ATRi) Tuvusertib + ATM Inhibitor (ATMi) Lartesertib in a Phase 1b Study of Patients with Advanced Unresectable Solid Tumours

Boni | Poster #2612

Phase 2 Study of Xevinapant + Chemoradiotherapy (CRT) vs Placebo + CRT in Patients with Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA SCCHN): A Post Hoc Activity Analysis by Blinded Independent Review Committee Evaluation

Bourhis | e-abstract #e18039

Real-World (rw) Treatment (tx) Patterns and Clinical Outcomes in Patients (pts) with Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC): Insights from the US Oncology Network Electronic Health Record (EHR)

Bupathi | e-abstract #e16551

Real-World (rw) Treatment (tx) Patterns, Sequencing, and Outcomes in US Patients (pts) with Locally Advanced or Metastatic Urothelial Cancer (la/mUC) Treated with Avelumab First-Line Maintenance (1LM)

Carson | e-abstract #e16621

Age and other Criteria Influencing Nontreatment of Patients with Locally Adanced or Metastatic Urothelial Carncinoma: Results of a Physician Survey in 5 European Countries

Gupta | Poster #4570

Costs Associated with Novel First-Line (1L) Treatments in Patients (pts) with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) from a United States (US) Medicare and Commercial Payer Perspective

Ike | e-abstract #e16552

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes from JAVELIN Bladder 100 Trial Patients with Histological Subtypes

Loriot | Poster #4567

Health-Related Quality of Life (HRQoL) with Tepotinib in Patients with MET Exon 14 (MET ex14) Skipping Non-Small Cell Lung Cancer (NSCLC) with Brain, Liver, Adrenal or Bone Metastases in the Phase II VISION Trial

Reinmuth | Poster #8575

Informing Optimal Treatment (tx) Sequences for Platinum-Eligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) in the United States: Results of a Clinical Simulation Modeling Exercise

Sanchez Alvarez | e-abstract #e13514

Pharmacokinetic (PK) and Pharmacodynamic (PD) Findings from a Phase 1b Study of ATR Inhibitor Tuvusertib + Anti-PD-L1 Avelumab in Patients with Advanced Unresectable Solid Tumors

Tolcher | Poster #2614